Semaglutide

GLP-1S:

Dosage, Benefits,

and Research Explained

GLP-1S is a GLP-1 receptor agonist originally developed for type 2 diabetes, but it has gained widespread popularity for weight loss and appetite control. It mimics the body’s natural GLP-1 hormone, regulating blood sugar, slowing digestion, and reducing hunger, making it one of the most effective FDA-approved weight loss peptides available.

Unlike stimulant-based fat burners, GLP-1S works naturally with your body’s hunger signals to create sustainable weight loss.

GLP-1 Analogue

CAS Number: 2023788-19-2

Formula: C225H438N48068

Purchase

Purchase from our preferred vendor: Project Zero

Use Case Common Dosage Frequency Duration Notes
Weight Loss & Appetite Suppression 0.25 mg Once weekly 4 weeks Start with **low dose**, gradually increase.
Increased Fat Burning & Metabolic Boost 0.5 mg Once weekly 4-8 weeks Best combined with **exercise & high-protein diet**.
Long-Term Weight Management 1.0 mg Once weekly Ongoing Monitor for **nausea, adjust dose as needed**.

How It Works

GLP-1S activates GLP-1 receptors, leading to:

✔ Slower gastric emptying – Makes you feel full longer.
✔ Reduced appetite & cravings – Lowers caloric intake naturally.
✔ Improved insulin sensitivity – Stabilizes blood sugar & prevents fat storage.
✔ Enhanced fat oxidation – Encourages body fat breakdown for energy.
✔ Cardiovascular & metabolic benefits – Lowers inflammation & protects the heart.

With once-weekly injections, GLP-1S offers a long-acting solution for weight loss and metabolic health.

 

Research-Backed Benefits

1. Extreme Weight Loss & Appetite Control

  • Reduces hunger & cravings, leading to caloric deficit & rapid weight loss.
  • Works best combined with a high-protein, low-carb diet.

2. Blood Sugar & Insulin Regulation

  • Improves insulin sensitivity, preventing fat storage & metabolic disorders.
  • Reduces risk of type 2 diabetes & insulin resistance.

3. Increased Fat Burning & Metabolic Boost

  • Enhances fat oxidation & energy expenditure.
  • Helps burn visceral (belly) fat more effectively.

4. Cardiovascular & Inflammation Benefits

  • Reduces inflammation & oxidative stress, improving heart health.
  • Lowers cholesterol & blood pressure.

5. Long-Term Weight Management

  • Resets metabolic set point, preventing weight regain after dieting.
  • Supports sustainable weight loss & overall health.

 

Conclusion

GLP-1S is a game-changing peptide for weight loss, providing appetite suppression, fat burning, and metabolic optimization. With once-weekly dosing and long-term benefits, it remains one of the most effective tools for sustainable weight management.

How does GLP-1S compare to other weight loss peptides?

✔ GLP-1S vs. GLP-1T has dual action (GLP-1 & GIP), leading to faster weight loss.
✔ GLP-1S vs. AOD 9604 – AOD 9604 enhances fat burning, but does not suppress appetite like GLP-1S.

  • Appetite suppression: Within 1-2 weeks.
  • Significant weight loss: Noticeable within 4-8 weeks.
  • Best results: Achieved in 12+ weeks with consistent use.
  •  

GLP-1S is well-tolerated, but potential mild side effects include:
✔ Nausea or upset stomach (common in first few weeks)
✔ Mild fatigue (due to caloric restriction)
✔ Temporary digestive discomfort

Tip: Start with a low dose and increase gradually to reduce nausea.

Can GLP-1S be stacked with other peptides?

Yes! Some popular stacks for enhanced effects include:
✔ GLP-1S + AOD 9604 → For maximum fat loss & appetite suppression.
✔ GLP-1S + GLP-1T → For extreme metabolic enhancement.
✔ GLP-1S + CJC-1295 + Ipamorelin → For fat loss with muscle preservation.

 

Referenced Citations

  1. Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. [Online].
    Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  2. Marso, S.P., et al. (2016). GLP-1 and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 375(19), 1834-1844. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/27633186/
  3. Bachem. (2024). GLP-1 Peptide API Manufacturer & Supply. [Online].
    Available: https://www.bachem.com/all-generic-apis/semaglutide/
  4. Smits, M.M., and Van Raalte, D.H. (2021). Safety of GLP-1. Front Endocrinol, 12, 1-19. [Online].
    Available: https://www.frontiersin.org/articles/10.3389/fendo.2021.645563/full
  5. Aroda, V.R., et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral GLP-1 Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 42(9), 1724-1732. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/31186300/
Scroll to Top